Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash from Investing Activities (2016 - 2025)

Vanda Pharmaceuticals' Cash from Investing Activities history spans 16 years, with the latest figure at $44.9 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 1023.62% year-over-year to $44.9 million; the TTM value through Dec 2025 reached $94.9 million, up 644.23%, while the annual FY2025 figure was $94.9 million, 644.23% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was $44.9 million at Vanda Pharmaceuticals, up from $21.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $187.3 million in Q1 2023 and bottomed at -$190.9 million in Q2 2023.
  • The 5-year median for Cash from Investing Activities is -$7.3 million (2021), against an average of $1.9 million.
  • The largest annual shift saw Cash from Investing Activities crashed 1351.13% in 2021 before it soared 15204.23% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at -$26.0 million in 2021, then soared by 390.13% to $75.4 million in 2022, then tumbled by 158.05% to -$43.8 million in 2023, then skyrocketed by 109.12% to $4.0 million in 2024, then surged by 1023.62% to $44.9 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Cash from Investing Activities are $44.9 million (Q4 2025), $21.4 million (Q3 2025), and -$15.3 million (Q2 2025).